ArticleOncotarget2016
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.International journal of oncology · 2019Pooled it
- Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Rare prostate cancer histologies: detection, characteristics and treatment.Nature reviews. Urology · 2026Review
- Non-conventional histologies of prostate cancer: from morphology to biology-driven precision oncology.The oncologist · 2026Review
- TMB-High, MSI-High Castration-Resistant Prostate Cancer Treated With Pembrolizumab.IJU case reports · 2025Article
- Prevalence of Mismatch Repair Deficiency in Primary Prostate Cancer in a Large Prospective Cohort.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- [Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate].Urologie (Heidelberg, Germany) · 2025Article
- Assessment of mismatch repair proteins (MLH1 and MSH2) and p53 immunohistochemical expression in prostatic carcinoma: association with different clinicopathologic characteristics.Ecancermedicalscience · 2025Article
- Solitary testicular metastasis post-prostatectomy for prostatic ductal adenocarcinoma: case report and literature review.Frontiers in oncology · 2025Article
- Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing.World journal of oncology · 2024Article
- Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care.Cancers · 2024Article
- Article
- The Somatic Mutational Landscape of Mismatch Repair Deficient Prostate Cancer.Journal of clinical medicine · 2023Article
- DNA repair deficiency as circulating biomarker in prostate cancer.Frontiers in oncology · 2023Review
- Progression in immunotherapy for advanced prostate cancer.Frontiers in oncology · 2023Review
- Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China.Frontiers in oncology · 2023Article
- WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer.Histopathology · 2022Review
- Article
- Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.The Prostate · 2022Article
- A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer.Molecular cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Precision oncology entails making treatment decisions based on a tumor's molecular characteristics. For prostate cancer, identifying clinically relevant molecular subgroups is challenging, as molecular profiling is not routine outside of academic centers. Since histologic variants of other cancers correlates with specific genomic alterations, we sought to determine if ductal adenocarcinoma of the prostate (dPC) - a rare and aggressive histopathologic variant - was associated with any recurrent actionable mutations. Tumors from 10 consecutive patients with known dPC were sequenced on a targeted next-generation DNA sequencing panel. The median age at diagnosis was 59 years (range, 40-73). Four (40%) patients had metastases upon presentation. Archival tissue from formalin-fixed paraffin-embedded prostate tissue samples from nine patients and a biopsy of a metastasis from one patient with castration-resistant prostate cancer were available for analysis. Nine of 10 samples had sufficient material for tumor sequencing. Four (40%) patients' tumors had a mismatch repair (MMR) gene alteration (N = 2, MSH2; N = 1, MSH6; and N = 1, MLH1), of which 3 (75%) had evidence of hypermutation. Sections of the primary carcinomas of three additional patients with known MMR gene alterations/hypermutation were histologically evaluated; two of these tumors had dPC. MMR mutations associated with hypermutation were common in our cohort of dPC patients. Since hypermutation may predict for response to immune checkpoint blockade, the presence of dPC may be a rapid means to enrich populations for further screening. Given our small sample size, these findings require replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.